Clover Biopharma Gets Critical Cash Booster After Covid Vaccine Approval
The innovative drug maker announced a major share sale a day after its self-developed Covid-19 vaccine got the green light for emergency use in ChinaKey Takeaways:Clover Biopharmaceuticals raised $64 million…
RELATED ARTICLES
-
Dispute over Covid vaccines casts doubt on Clover Bio recovery
2197.HK -
Everest Medicines eyes mRNA tumor vaccines as drug valuations rebound
1952.HK
-
Everest Medicines drives growth with AI-powered mRNA pipeline
1952.HK
-
Zhengye Biotech’s ‘pet-sized’ IPO leaves plenty of room for more fundraising
ZYBT.US
-
WuXi Biologics sells vaccine plant as new U.S. law looms
2269.HK
-
Everest gets boost from core product Nefecon’s inclusion in China’s national health plan
1952.HK
- As Covid drug cash dwindles, Vigonvita targets new remedies
